Arcturus’ lead clinical stage product candidates include a first-in-class, self-amplifying mRNA vaccine for COVID-19 and an mRNA replacement therapy for ornithine transcarbamylase (OTC ...

The Arcturus subvariant stems from the Omicron strain of Covid-19 and is known as XBB.1.16 since it descends from the recombinant variant XBB, which combines two sublineages of Omicron BA.2.

The Ministry of Health, Labour and Welfare (MHLW) gave the green light to CSL and Arcturus’ COVID-19 vaccine ARCT-154 – also known as Lunar-COV19 – which will be commercialised in Japan by ...

The Japanese drugs giant Takeda and the US biotech Arcturus Therapeutics have joined the hunt for therapies for the COVID-19 coronavirus. As the infection and death count continues to rise across ...

The Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing ("Rospotrebnadzor") sees a risk of the increased incidence of infections with the Arcturus COVID-19 ...

CEO of Arcturus. "This approval highlights the clinical promise of KOSTAIVE and its ability to protect against the ever-changing COVID-19 virus." About sa-mRNA mRNA vaccines help protect against ...